Preeclampsia, a severe unpredictable complication of pregnancy, occurs in 6% of pregnancies, usually in the second or third trimester. The specific etiology of preeclampsia remains unclear, although the pathophysiological hallmark of this condition appears to be an inadequate blood supply to the placenta. As a result of the impaired placental blood flow, intrauterine growth restriction (IUGR) and consequential fetal oxidative stress may occur. Consistent with this view, pregnancies complicated by preeclampsia and IUGR are characterized by up-regulation of key transcriptional regulators of the hypoxic response including, hif1α and as well as p53 and its target genes. Recently, the presence of circulating cell-free fetal RNA has been documented in maternal plasma. We speculated that pregnancies complicated by preeclampsia and IUGR, will be associated with an abnormal expression of p53 and/or hif1α related genes in the maternal plasma. Maternal plasma from 113 singleton pregnancies (72 normal and 41 complicated pregnancies) and 19 twins (9 normal and 10 complicated pregnancies) were collected and cell free RNA was extracted. The expression of 18 genes was measured by one step real-time RT-PCR and was analyzed for prevalence of positive/negative expression levels. Results indicate that, among the genes examined, cell free plasma expressions of p21 and hif1α were more prevalent in pregnancies complicated by hypoxia and/or IUGR (p<0.001). To conclude, we present in this manuscript data to support the association between two possible surrogate markers of hypoxia and common complications of pregnancy. More work is needed in order to implement these findings in clinical practice.
References
[1]
Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R (2010) Pre-eclampsia. Lancet 376: 631–644.
[2]
Kinzler WL, Vintzileos AM (2008) Fetal growth restriction: a modern approach. Curr Opin Obstet Gynecol 20: 125–131.
[3]
Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649–658.
[4]
Pallotto EK, Kilbride HW (2006) Perinatal outcome and later implications of intrauterine growth restriction. Clin Obstet Gynecol 49: 257–269.
[5]
McIntire DD, Bloom SL, Casey BM, Leveno KJ (1999) Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 340: 1234–1238.
[6]
Bracken CP, Whitelaw ML, Peet DJ (2003) The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60: 1376–1393.
[7]
Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294–309.
[8]
Loboda A, Jozkowicz A, Dulak J (2010) HIF-1 and HIF-2 transcription factors–similar but not identical. Mol Cells 29: 435–442.
[9]
Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677–684.
[10]
Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230–1237.
[11]
Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771–17778.
[12]
Semenza GL (2010) Vascular responses to hypoxia and ischemia. Arterioscler Thromb Vasc Biol 30: 648–652.
[13]
Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15: 621–627.
[14]
Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, et al. (2000) Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 105: 577–587.
[15]
Nishi H, Nakada T, Hokamura M, Osakabe Y, Itokazu O, et al. (2004) Hypoxia-inducible factor-1 transactivates transforming growth factor-beta3 in trophoblast. Endocrinology 145: 4113–4118.
[16]
Patel J, Landers K, Mortimer RH, Richard K (2010) Regulation of hypoxia inducible factors (HIF) in hypoxia and normoxia during placental development. Placenta 31: 951–957.
[17]
Schaffer L, Scheid A, Spielmann P, Breymann C, Zimmermann R, et al. (2003) Oxygen-regulated expression of TGF-beta 3, a growth factor involved in trophoblast differentiation. Placenta 24: 941–950.
[18]
El-Salahy EM, Ahmed MI, El-Gharieb A, Tawfik H (2001) New scope in angiogenesis: role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females. Clin Biochem 34: 323–329.
[19]
Helske S, Vuorela P, Carpen O, Hornig C, Weich H, et al. (2001) Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 7: 205–210.
[20]
Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, et al. (1997) Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 38: 302–306.
[21]
Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24: 147–158.
[22]
Junttila MR, Evan GI (2009) p53–a Jack of all trades but master of none. Nat Rev Cancer 9: 821–829.
[23]
Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, et al. (2001) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20: 2225–2234.
[24]
Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, et al. (2001) DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 20: 3449–3455.
[25]
Aylon Y, Oren M (2007) Living with p53, dying of p53. Cell 130: 597–600.
[26]
Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26: 2202–2211.
[27]
Levy R, Smith SD, Yusuf K, Huettner PC, Kraus FT, et al. (2002) Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression. Am J Obstet Gynecol 186: 1056–1061.
[28]
Ng EK, Tsui NB, Lau TK, Leung TN, Chiu RW, et al. (2003) mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A 100: 4748–4753.
[29]
Poon LL, Leung TN, Lau TK, Lo YM (2000) Presence of fetal RNA in maternal plasma. Clin Chem 46: 1832–1834.
[30]
Hahn S, Rusterholz C, Hosli I, Lapaire O (2011) Cell-free nucleic acids as potential markers for preeclampsia. Placenta 32: SupplS17–20.
[31]
Maron JL, Johnson KL, Slonim D, Lai CQ, Ramoni M, et al. (2007) Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood. J Clin Invest 117: 3007–3019.
[32]
Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES (2005) Birth weight standards in the live-born population in Israel. Isr Med Assoc J 7: 311–314.
[33]
Bulletins–Obstetrics ACoP (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99: 159–167.
[34]
Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, et al. (2002) Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 48: 1212–1217.
[35]
Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE (2008) Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 102: 146–151.
[36]
Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, et al. (2007) Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196: 326 e321–313.
[37]
Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, et al. (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198: 175 e171–176.
[38]
Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, et al. (2007) Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 27: 258–263.
[39]
Scazzocchio E, Figueras F (2011) Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 23: 65–71.
[40]
Dennis Lo YM, Chiu RW (2007) Prenatal diagnosis: progress through plasma nucleic acids. Nat Rev Genet 8: 71–77.
[41]
Mouillet JF, Chu T, Hubel CA, Nelson DM, Parks WT, et al. (2010) The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta 31: 781–784.
[42]
Pang WW, Tsui MH, Sahota D, Leung TY, Lau TK, et al. (2009) A strategy for identifying circulating placental RNA markers for fetal growth assessment. Prenat Diagn 29: 495–504.
[43]
Farina A, Sekizawa A, Purwosunu Y, Rizzo N, Banzola I, et al. (2006) Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. Prenat Diagn 26: 1115–1120.
[44]
Tal R, Shaish A, Barshack I, Polak-Charcon S, Afek A, et al. (2010) Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol 177: 2950–2962.
[45]
Heazell AE, Sharp AN, Baker PN, Crocker IP (2011) Intra-uterine growth restriction is associated with increased apoptosis and altered expression of proteins in the p53 pathway in villous trophoblast. Apoptosis 16: 135–144.
[46]
Sharp AN, Heazell AE, Crocker IP, Mor G (2010) Placental apoptosis in health and disease. Am J Reprod Immunol 64: 159–169.
[47]
Purwosunu Y, Sekizawa A, Okazaki S, Farina A, Wibowo N, et al. (2009) Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol 200: 386 e381–387.
[48]
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, et al. (2007) Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med 13: 218–223.
[49]
Barkehall-Thomas A, Tong S, Baker LS, Edwards A, Wallace EM (2006) Maternal serum activin A and the prediction of intrauterine growth restriction. Aust N Z J Obstet Gynaecol 46: 97–101.
[50]
Markestad T, Bergsjo P, Aakvaag A, Lie RT, Jacobsen G, et al. (1997) Prediction of fetal growth based on maternal serum concentrations of human chorionic gonadotropin, human placental lactogen and estriol. Acta Obstet Gynecol Scand Suppl 165: 50–55.
